The Sky Shop For Hope
Women's Quarter Zip (Embroidered SKY Logo)
Women's Quarter Zip (Embroidered SKY Logo)
Couldn't load pickup availability
More than just a style staple, this quarter zip supports an important cause. 40% of all revenue from the Champion Spirit Support Quarter Zip goes to Sky Foundation, a non-profit that funds pancreatic cancer research, allowing every purchase to make an impact.
Made from 95% recycled polyester, 5% spandex for a lightweight, elastic feel
Fabric weight: 5.5 oz./yd² (186.48 g/m²) for all-day comfort
Athletic fit with self-fabric cuffs and waistband
Triple-needle stitch details for added durability at cuffs, waistband, shoulders, and back yoke
Heat-sealed neck label for a smooth finish
Size guide
SHIRT LENGTH (inches) | SHIRT WIDTH (inches) | SLEEVE LENGTH (inches) | |
S | 27 ½ | 19 | 35 ¼ |
M | 28 ½ | 21 | 36 |
L | 29 ½ | 23 | 36 ¾ |
XL | 30 ½ | 25 | 37 ½ |
2XL | 31 ½ | 27 | 38 ¼ |
SHIRT LENGTH (cm) | SHIRT WIDTH (cm) | SLEEVE LENGTH (cm) | |
S | 69.9 | 48.3 | 89.5 |
M | 72.4 | 53.3 | 91.4 |
L | 75 | 58.4 | 93.4 |
XL | 77.5 | 63.5 | 95.3 |
2XL | 80 | 68.6 | 97.2 |
Share






Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...